Antibody as carrier of 131I in cancer diagnosis and treatment.
Cell-surface localizing heterologous antibodies against mouse EL4 lymphoma, Ehrlich ascites carcinoma, and several human malignant tumors could be bound to varying amounts of 131I without interfering with the reactivity of these antibodies with their respective tumor cells. Exposure of the mouse tumor cells to radio-iodinated antitumor antibodies in vitro, or the injection of radio-iodinated antitumor antibodies into mice preinoculated with tumor cells resulted in either partial or complete tumor inhibition depending upon the amount of 131I activity carried by the antibodies. Injection of comparable amounts of the immunoglobulin alone or of 131I bound to normal globulin did not cause any tumor inhibition. Intraperitoneally injected radio-iodinated anti-EL4 antibody was found to localize preferentially in the subcutaneous transplants of EL4 lymphoma. Similar localization of intravenously injected radio-iodinated antibodies was observed in the metastases of two cancer patients.
D000818:Animals; D000910:Antibodies, Heterophile; D000912:Antibodies, Neoplasm; D000918:Antibody Specificity; D002286:Carcinoma, Ehrlich Tumor / Q000532:radiotherapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008223:Lymphoma / Q000532:radiotherapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis / Q000175:diagnosis; D009369:Neoplasms / Q000175:diagnosis* / Q000532:radiotherapy*; D009374:Neoplasms, Experimental / Q000532:radiotherapy
D000910:Antibodies, Heterophile; D000912:Antibodies, Neoplasm; D007457:Iodine Radioisotopes